Want to see AU:VHL full AI Analyst Report?
Top Page
Vitasora Health
(Sydney:VHL)
Select Model
Select Model
Rating:49Neutral
Price Target:
AU$0.02
▲(50.00% Upside)
Action:N/A
Date:08/29/26
The score is held down primarily by weak financial performance driven by heavy losses, negative gross profit, and significant cash burn, partially offset by a debt-free balance sheet. Technicals are moderately supportive in the near term (positive MACD and price above key short-term averages), while valuation remains challenging due to negative earnings and no dividend yield.
Positive Factors
Strong revenue growth
Rapid annual revenue growth indicates improving commercial traction and expanding demand. If sustained, this scale can strengthen the operating model and create a larger base from which the company may eventually improve margins.
Negative Factors
Severely weak profitability
Costs exceeding revenue at the gross-profit level indicate the business is not yet covering direct operating expenses. Deep losses across EBITDA, EBIT, and net income weaken internal funding capacity and show that scalable economics have not been established.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
Rapid annual revenue growth indicates improving commercial traction and expanding demand. If sustained, this scale can strengthen the operating model and create a larger base from which the company may eventually improve margins.
Read all positive factors
Vitasora Health (VHL) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$35.23M
Dividend YieldN/A
Average Volume (3M)1.81M
Price to Earnings (P/E)―
Beta (1Y)1.48
Revenue Growth38.59%
EPS Growth19.44%
CountryAU
Employees30
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding2,348,677,200
10 Day Avg. Volume706,842
30 Day Avg. Volume1,813,321
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.25
Price to Sales (P/S)4.73
P/FCF Ratio-2.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$11.80M
Vitasora Health Business Overview & Revenue Model
Company Description
Headquartered in Melbourne, Australia, Vitasora Health Limited specializes in the research, development, and market introduction of medical devices across Australia and the United States. The company's portfolio also includes the creation of mobil...
Vitasora Health Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
22
Negative
| Breakdown | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 4.28M | 456.91K | 70.53K | 253.69K | 270.07K |
| Gross Profit | -5.87M | 453.06K | -2.45M | -1.90M | -2.26M |
| EBITDA | -9.92M | -7.00M | -5.68M | -7.04M | -11.95M |
| Net Income | -10.61M | -7.13M | -5.78M | -6.62M | -11.04M |
Balance Sheet | |||||
| Total Assets | 18.84M | 6.19M | 3.18M | 4.21M | 9.11M |
| Cash, Cash Equivalents and Short-Term Investments | 3.06M | 791.36K | 146.16K | 1.22M | 7.97M |
| Total Debt | 0.00 | 1.29M | 149.13K | 70.66K | 142.47K |
| Total Liabilities | 2.71M | 3.55M | 2.35M | 1.20M | 1.54M |
| Stockholders Equity | 16.13M | 2.64M | 826.89K | 3.01M | 7.57M |
Cash Flow | |||||
| Free Cash Flow | -10.00M | -6.64M | -4.51M | -8.48M | -7.39M |
| Operating Cash Flow | -10.00M | -6.64M | -4.49M | -8.48M | -7.34M |
| Investing Cash Flow | -490.46K | -1.89M | -21.80K | -2.27K | -54.25K |
| Financing Cash Flow | 13.25M | 9.13M | 3.46M | 1.64M | 11.79M |
Vitasora Health Technical Analysis
Positive
0.01
Price Trends
0.01
Positive
0.01
Positive
0.02
Negative
Market Momentum
<0.01
Negative
61.81
Neutral
72.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:VHL, the sentiment is Positive. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 61.81 is Neutral, neither overbought nor oversold. The STOCH value of 72.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AU:VHL.
Vitasora Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | AU$141.73M | 61.76 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$163.64M | -9.45 | -203.69% | ― | -1.53% | 28.29% | |
49 Neutral | AU$35.23M | -3.49 | -48.56% | ― | 38.59% | 19.44% | |
49 Neutral | AU$35.44M | -1.91 | -58.13% | ― | 2.08% | -195.31% | |
47 Neutral | AU$65.80M | -7.37 | -24.29% | ― | -17.35% | -47.29% | |
43 Neutral | AU$22.99M | -2.53 | -1688.04% | ― | 11.45% | 0.69% |
* Healthcare Sector Average
AU:VHL
Vitasora Health
0.02
-0.01
-42.31%
AU:ONE
Oneview Healthcare Chess Depository Interests repr 1
0.20
-0.04
-17.02%
AU:M7T
Mach7 Technologies
0.28
-0.03
-11.11%
AU:BMT
Beamtree Holdings Ltd
0.12
-0.11
-47.83%
AU:ALC
Alcidion Group Limited
0.11
0.02
16.67%
AU:PCK
PainChek Ltd
0.11
-0.33
-75.00%
Vitasora Health Corporate Events
Vitasora Health Files ASX Corporate Governance Statement for FY26
Aug 28, 2026
Vitasora Health Limited has lodged its corporate governance statement for the year ended 30 June 2026, confirming adherence to key ASX Corporate Governance Council recommendations. The statement, approved by the board and accessible through the co...
Vitasora Health Releases FY26 Annual Report and Sets FY27 Priorities
Aug 28, 2026
Vitasora Health Limited has released its annual report for the year ended 30 June 2026, outlining the company’s financial performance, governance disclosures, and key management commentary. The report includes a Chairman and CEO update, a fi...
Vitasora Health Narrows Loss as Revenue Jumps on vCare Platform Growth
Aug 28, 2026
Vitasora Health reported a 30.6% rise in revenue and other income to $4.84 million for the year to 30 June 2026, while narrowing its loss after tax slightly to $10.61 million as it continued to invest in its healthcare platform and patient growth....
Vitasora Health Posts Record Fee-for-Service Revenue as vCare Transition Boosts FY26 Performance
Jul 30, 2026
Vitasora Health reported strong operational momentum in the June 2026 quarter as its vCare platform moved from implementation to full execution. Record June fee-for-service revenue of US$239,000 within total monthly revenue of US$306,000, higher b...
Vitasora Health Issues Shares as Broker Fee in Capital Raising
Jul 3, 2026
Vitasora Health Limited has issued 800,000 fully paid ordinary shares as part of a broker fee linked to a recent placement capital raising. The company has confirmed that the shares were issued without a prospectus under Australian disclosure rule...
Vitasora Health Issues New Shares as Broker Fee on ASX
Jul 3, 2026
Vitasora Health Limited has applied for quotation of 800,000 new ordinary fully paid shares on the ASX, issued on July 2, 2026 as part of a broker fee arrangement. The shares represent a 4% fee calculated on the gross amount of funds received, ind...
Vitasora Health Options Expire, Trimming Potential Equity Overhang
Jun 22, 2026
Vitasora Health Limited has reported the expiry of 8,000,000 listed options, denominated as VHLAC, which lapsed unexercised on June 19, 2026. This cessation of options, notified to the ASX on June 22, 2026, reduces the pool of potential future equ...
Vitasora Health Issues 400 Million New Shares Under Placement, Confirms Compliance Status
Jun 17, 2026
Vitasora Health Limited has issued 400,000,000 fully paid ordinary shares as part of a placement capital raising announced earlier in June, expanding its capital base to support its operations in remote healthcare and connected care services. The ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.